PERSONAL INFORMATION
Name: Yu Yu
Gender: male
Title: professor
Position: Vice-president（2006—2020）
CONTACT INFORMATION
Email: yuyu3519@163.com
Address: Chongqing Medical University，Yi Xue Yuan Road 1#，Yu Zhong District
Chongqing 400016, P.R China
Phone: +86-023-13983890728
EDUCATION EXPERIENCE
1985—1989: M.A. in Medicinal Chemistry at Chongqing University of Medical Sciences, Chongqing 400016, P.R China, Thesis: “Synthesis and antischistosomal activity of praziquantel analogues”.Diplopma: Master of Sciences
1978—l982: B.A. in Pharmacy, West China University of Medical Sciences, Chengdu 610041, P.R China
WORKING EXPERIENCE
2006—Present: Vice-president（2006—2020）, Professor at Department of Medicinal Chemistry, Chongqing Medical University
2000—2006: Professor at Res. Lab. Pharmaceutical Chem. And Biomterials, Chongqing Medical University
1993—2000: Associate professor at Res. Lab. Pharmaceutical Chem. And Biomterials, Chongqing Medical University
1988—1993: Lecturer at Department of Chemistry, Chongqing Medical University
1982—1988: Assistant at Department of Chemistry, Chongqing Medical University
RESEARCH INTERESTS
（1）New Drug Design, synthesis and technology research
（2）structure-activity relationship research
（3）targeted drug delivery system research
（4）liposomes
HONOUR & AWARDS
（1）Yu Y, GanZJ, Yuan JH,Li W, Li LJ and Gan LL. Preparation and application ,of a novel lipotoxicity-based molecular targeted antitumor drug TNBG-19，Third Prize of Chongqing Science and Technology Progress Award（2021）
（2）Yu Y, Chen ZQ, Yang XL , Li LJ and Tang WX. Development of an innovative non-cytotoxic anti-tumor drug TNBG and its injection， Third Prize of Chongqing Scientific and technological invention（2007）
Papers
（1）Linling Gan#，Zongjie Gan#，Yanrong Dan, Yaowei Li, Peiming Zhang, Shanwen Chen,Zaijun Ye,Tao Pan, Chunmei Wan, Xuelian Hu, and Yu Yu*.Tetrazanbigen Derivatives as Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) Partial Agonists: Design, Synthesis, Structure- Activity Relationship, and Anticancer Activities. Journal of Medicinal Chemistry，2021,64(2): 1018-1036.
（2）Jing Wang，Yingbo Li，Chun-Mei Wan，Zong-Jie Gan，Lin-Ling Gan，Bai-Cheng He，Yu Yu*，Xue-Lian Hu*. PTEN inhibition leads to the development of resistance to novel isoquinoline derivative TNBG-5602 in human liver cancer cells. American Journal of Cancer Research，2021;11(9):4515-4527
（3）Xuelian Hu , Chunmei Wan, Zongjie Gan，Rongxing Liu，Yongjie Chen，Jing Wang，
Linling Gan,Yuhang Chen，Yingbo Li，Baicheng He, and Yu Yu*.TNBG-5602, a novel derivative
of quinoxaline, inhibits liver cancer growth via upregulating peroxisome proliferatoractivated
receptor γ in vitro and in vivo. Journal of Pharmacy and Pharmacology, 2019,71(11):1684–1694.
（4） Xiang Chen, Yongjun Gan, Yu Yu* and Yuan Zhang*. Synthesis and evaluation of new
sterol derivatives as potential antitumor agents. RSC Adv, 2018, 8: 26528–26537.
（5）Xiaohong Zheng, Wei Li, Zuoping Lan, Xiaolan Yang, Longjiang Li, Yonghua Yuan,
Zhu Xia, Xunguan Chen, Xinyu Zhang, and Yu Yu*. Antitumour effects of tetrazanbigen against
human hepatocellular carcinoma QGY-7701 through inducing lipid accumulation in vitro and in
vivo. Journal of Pharmacy and Pharmacology. 2015, 67:1593-1602.
（6）Yonghua Yuan, Xiaolan Yang , Wei Li, Huabo Liu, Cong Luo, Hua Chen, Rong Gu,
and Yu Yu*. Antitumor effects of tetrazanbigen may be related to its interference with lipid
metabolism of human hepatocellular carcinoma cells.Scientific Research and Essays. 2011, 6
(13):2812-2818.
（7）Yonghua Yuan, Wei Li, Longjiang Li, Xiaolan Yang, Rong Gu, Huabo Liu, Kaishun
Huang, Yu Yu*. Effects of Tetrazanbigen on the Protein Expression in Human Hepatocellular
Carcinoma Cell Line QGY-7701. Journal of Huazhong University of Science and Technology
[Medical Sciences]. 2009, 29(3), 304-308.
（8）Wei Li, Yonghua Yuan, Zongwei Luo, Xiaohong Zheng, Ling Zhao, Wen Duan, Yu Yu*.
Bacterial expression, refolding, functional characterization and mass spectrometric identification
of full-length human PPAR-γ. Bioscience Biotechnology and Biochemistry. 2010, 74(6):
1173-1180.
（9）LiJuan Wang, Rui Li, KeKe Che, ZhongHong Liu, ShiFeng Xiang, MengYa Li, Yu Yu*.Enhanced antitumor effect on intrapulmonary tumors of docetaxel lung-targeted liposomes in a rabbit model of VX2 orthotopic lung cancer. Scientific Reports,DOI：10.1038/s41598-017-10530-8
（10）Ling Zhao, Yumeng Wei，Wei Li，Yu Liu, Ya Wang，Xiaodong Zhong，and Yu Y*，Solid dispersion and effervescent techniques used to prepare docetaxel liposomes for lung-targeted delivery system: in vitro and vivo evaluation, J.Drug Target，2011,19(3):171-178.
（11）Li W, Yuan YH, Luo ZW, Zheng XH, Zhao L, Duan w, Yu Y*. Bacterial expression, refolding, functional characterization, and mass spectrometric identification of full-length human PPAR-γ. Biosci Biotechnol. Biochem,2010(74):1173-1180
（12）Ling Zhao, Yumeng Wei，Xiaodong Zhong，Yan Liang，Xuemei Zhang，Wei. Li ，Bibo Li， Ya Wang，and Yu Y*, PK and tissue distribution of docetaxel in rabbits after i.v. administration of liposomal and injectable formulations, J. Pharm. Biomed. Anal. 2009,49(2):989-996.
（13）Chen ZQ，Yu Y*, Li LJ. High-performance liquid chromatographic resolution of 1-(1,4-benzodioxane-2-formyl) piperazine enantiomers after chiral derivatization. Journal of Separation Science，2005，28(2)：193-196.
（14） Yu Y and Yan SH， “Synthesis of l-alkyl Reissert compounds of isoquinoline and their hydrogenation.”Youji Huaxue， 2000，20（1）：28（CA2000，132(24):321793a）
（15）Yu Y，Yan SH，Hu XL and Jin HW，Wang XG and Zhao C，“The preparation of liposome of levo-praziquantel and praziquantel and their comparative efficacy in experimental therapy of schitosomiasis in mice.”Huaxi Yaoxue Zazhi，1999，14(5-6):2l7
（16）Yu Y，Jin HW，Hu XL and Yan SH，“Syntheses of antiviral drug trisodium phosphonoforate.” Chinese Journal of Pharmaceuticals，1995，26(9):390
（17）Yu Y and Yan SH，“Improved synthesis of thiazolidine-2-thione.” Chinese Journal of Pharmaceuticals，1994，25（2）：85 (CA 1994, 121(2):157561y)
（18）Yu Y and Jin HW，“Synthesis of laurocapram by liquid-liquid phasetransfer catalysis.” Acta universitatis scientiae medicinae chongqing,l994，19 (1):12
（19）Yu Y，Jin HW，Hu XL and Yan SH，“Studies on synthesis of antiviral drug trisodium phos- phonoforate.” Chinese Journal of Pharmaceuticals， 1994，4（1）：57 (CA 1995, 122(5):56108w)
（20）Yu Y，Jin HW，Hu XL and Yan SH，“Determination of the antiviral drug trisodium phosphonoforate and its preparations.” Acta universitatis scientiae medicinae chongqing，l999，24 (3):244
（21）Yu Y and Yan SH，“Studies on C1 alkylation of reissert compound of isoquinoline.”Acta universitatis scientiae medicinae chongqing，l992，17 (3):172
（22）Yu Y and Yan SH，“Synthesis and antischistosomal activity of praziquantel analogues.” Chinese Journal of Phatngaceutlcals，1991，22(9):398(CA 1992 ,117(13):123897u
（23）Yu Y and Yan SH，“Synthesis of praziquantel analogues and their Antischistosomal activity in vitro, International symposium on new drug research and development.”《collection of papers and abstracts》，p219，October，22~25，1991，BEIJING CHINA
（24） Li WY，Yu Y and Jin HW，“Studies on sythesis of enalapril，a new Angiotensinconverting enzyme inhibitor.”Chinese journal of medicinal chemistry，1995，5(3):218 (CA 1996，124: 261674k)
（25）Hu XL，Yu Y and Yan SH，“Synthesis of antiinflammatory and antiulcer drug zinc acexamate.”Chinese journal of medicinal chemistry，1998，8(3):218
（26）Qiu F，Li KF，Yu Y and Qiu ZY，“WWW and chemistry.” Huaxue Tongbao 1997，7:44(CA 19979127(14): 198249z)
（27）Li HZ，Zhao H，Yu Y and Qiu ZY，“Determination of the purity praziquanamine by reversed-phase high-performance liquid chromatography after derivatization with 2,3,4,6-tetra-O- acetyl-β-D-glucopyranosyliothiocyanate.”Acta Pharmaceutica Sinica，1993，28(6):450 (CA 1993, 119:188721p;AA l993,56(2):2G7l)
（28） Li HZ，Zhao H，Yu Y and Qiu ZY，“Reversed-phase high-performance liquid chromatographic study on the separation of amino acids stereo-Isomers after chiral derivatization with 2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyliothiocyanate.” Chinese Journal of Analytical Chemistry，1993,21(10):1156 (CA 1994，120:152650w，AA 1994, 56(5)，5F235)
（29）Yan SH，Chen BY，Li JS，Yu Y and Lu RJ，“Molecular and crystal structure of dextro- and levo-praziquantel and their antischistosomal activity，International symposium on new drug research and development. Collection of papers and abstracts，p180，October，22~25，1991，BEIJING CHINA
（30）Zhao C，Waug XG，Liu YB，Yu DG and Yu Y，“Levo-praziquantel liposome and praziquantel liposome therapy of schistosomiasis in mice.” Zhongguo RenShou GongHuan Zazhi，1997，13(3):31
Patents
（1）Yu Y，Gan ZJ，Gan LL and Chen Q. A novel lipotoxicity-based molecular targeted antitumor azosteroid derivatives, preparation method and application. Chinese Patent No.202110026819.5.
（2）Yu Y，Zhao L，.Li W，Zhong XD, Liang Y and Zhang XM. Use of lung targeting drug-loaded liposomes and their precursors for Injection. Chinese Patent No.200910103135.X.
（3）Yu Y，Li W，Liu Y，Zhao L. Lung-targeted liposome drug composition for Injection. PCT，No. PCT/CN2010/ 070342.
